37 results about "Dimethyl-L-arginine" patented technology

The invention relates to a latex enhanced immunoturbidimetry kit for the detection of asymmetric dimethylarginine content. Specifically, the invention relates to a latex enhanced immunoturbidimetry kit for the detection of asymmetric dimethylarginine (ADMA) content in human blood samples. The kit comprises a mouse anti-human monoclonal antibody solution, an ADMA-human Serum albumin complex crosslinked latex particle expansion and an ADMA calibrator. According to the method, by the utilization of competitive binding of free ADMA in blood and ADMA crosslinked on the surface of latex particles to ADMA monoclonal antibody, turbidity formed by the reaction between the ADMA-crosslinked latex particles and ADMA monoclonal antibody is reduced. Therefore, the content of ADMA is detected through the reduction degree of turbidity. The kit provided by the invention can be applied in a biochemical analyzer commonly-used in clinic, is convenient and rapid to operate and has strong specificity. Both sensitivity and detection range of the kit can satisfy clinic application needs.

Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.

The invention discloses a reagent kit and method for measuring the concentration of asymmetric dimethylarginine. The reagent kit comprises a reagent 1 and a reagent 2, wherein the reagent 1 is prepared from latex particles coated with monoclonal antibodies resisting asymmetric dimethylarginine, and the reagent 2 is prepared from latex particles coated with asymmetric dimethylarginine-inert carrier conjugates. When the reagent kit is adopted for detecting asymmetric dimethylarginine, immune turbidity can be easily improved, detection signals can be easily amplified, the reagent kit has the advantages of being free of special instruments, easy and convenient to operate, high in sensitivity and low in cost, rapid and large-flow clinical sample testing can be achieved, it is made possible that asymmetric dimethylarginine becomes a clinical conventional detection item, and the reagent kit has high economic value.

The invention relates to a urine protein marker for ovarian cancer and abdominal cavity transplantation tumors and diagnosis application thereof, in particular to a urine protein marker obtained by using a rat ovarian cancer cell abdominal cavity transplantation tumor model and mass spectrometry, and application in diagnosis and disease course monitoring of human ovarian cancer and abdominal cavity transplantation tumors. The urine protein marker is selected from cell adhesion molecules 4, alcohol dehydrogenase 1, N(G), N(G)-dimethylarginine 1, methyl mercaptan oxidase, phosphotriesterase related protein, an Rab GDP dissociation inhibitor beta and the like. Urine differential protein obtained from the marker provides simpler, quicker and non-invasive choice for early diagnosis and diseasecourse monitoring of ovarian cancer and abdominal cavity transplantation tumors.

The invention relates to the technical field of measuring and testing and discloses an enzymological detection method for detecting concentrations of citrulline, asymmetric dimethylarginine and the like in a reaction system by ATP (adenosine triphosphate) detection. According to the basic principle of reaction, ADMA (asymmetric dimethylarginine) is hydrolyzed by dimethylarginine dimethylaminohydrolase to obtain citrulline; in the presence of ADP (adenosine diphosphate) and Mg2+, the citrulline is subjected to coupling catalysis through ornithine carbamoyl transferase and carbamyl phosphokinase to finally obtain ornithine, carbon dioxide, ammonia, and ATP, and the released ATP is detectable by reagents. The enzymological detection method has the main advantages that reaction is sensitive, quick and highly accurate, the price is low, the ADMA or citrulline with the least concentration of 0.1 micromol/L can be detected, the detected concentration is approximate to the concentration of the ADMA in normal physiological serum and is far lower than the concentration of citrulline in the normal physiological serum, and a new available method for clinical ADMA detection is provided.

The invention discloses an asymmetric dimethylarginine high-efficiency detection method. The method is suitable for detecting content of asymmetric dimethylarginine in a sample, and the method comprises the following steps: obtaining an asymmetric dimethylarginine quantitative criterion rectification curve; preparing a detection product; separating the asymmetric dimethylarginine by high-flux liquid chromatography; detecting the asymmetric dimethylarginine by tandem mass spectrometry; and obtaining the content of the asymmetric dimethylarginine. The method uses the high-flux liquid chromatography-tandem mass spectrometry for rapidly and efficiently detecting the content of the asymmetric dimethylarginine in a biological sample.

The invention relates to a mutant protein comprising at least a fragment of a mutant dimethylarginine dimethylaminohydrolase (DDAH) enzyme, wherein the fragment possesses an affinity for asymmetric N,N-dimethyl arginine (ADMA) and/or L,N-monomethylarginine (LNMMA), which exists at lower plasma levels than ADMA, and is deficient in hydrolyzing ADMA or LNMMA to citrulline, releasing citrulline, or both.